# Philip Tagari

> Philip Tagari is a venture - series unknown investor at Amgen Ventures backing Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures)
- Location: Los Angeles, United States
- Total investments: 3
- Last investment: Sep 2022
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/philip-tagari-793719b/

Philip Tagari is a venture - series unknown investor at Amgen Ventures in Los Angeles focused on Biotechnology and Medical. Philip Tagari is based out of Los Angeles, California and is the Chief Scientific Officer of insitro. Philip Tagari attended Gonville & Caius College.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 100% |
| Medical | 2 | 67% |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |
| Therapeutics | 1 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 2 | 67% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Singapore | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ImmunoScape | ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The company’s Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, andvisualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. | $14M | Venture - Series Unknown | Sep 20, 2022 |  |
| BigHat Biosciences | BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatmentsfor patients suffering from today’s most challenging diseases. | $75M | Series B | Jul 20, 2022 |  |
| GPB Scientific | GPB Scientific is a biotechnology company that markets its technology to life sciences companies and research establishments. The company has accumulated an extensive portfolio of patents and know-how utilizing microchip technology for size-based enrichment and/or for affinity-based cell capture.The company was founded in 2002 andheadquartered in Richmond, Virginia. | $18M | Venture - Series Unknown | May 27, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [S32](https://shizune.co/investors/profile/section-32) — VC Fund, 2 deals together
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 1 deal together
- [AME Cloud Ventures](https://shizune.co/investors/profile/ame-cloud-ventures) — VC Fund, 1 deal together
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 1 deal together
- [Anzu Partners](https://shizune.co/investors/profile/anzu-partner) — VC Fund, 1 deal together
- [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 1 deal together

## About Amgen Ventures

VC Fund · San Francisco, United States

Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.

2 contacts available at Amgen Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Suzanne Blaug | SVP, Global Marketing and Commercial Development | https://shizune.co/investors/profile/suzanne-blaug |
| Philip Tagari | VP Research | https://shizune.co/investors/profile/philip-tagari |

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Philip Tagari invest in?

Philip Tagari invests primarily in Biotechnology, Medical and Health Care startups, most often at Venture - Series Unknown and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Philip Tagari last invest?

The most recent investment recorded for Philip Tagari closed in Sep 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co